Subject demographics and baseline disease characteristics (ITT population)
| Subject characteristics | Infliximab plus methotrexate (n=56) | Methotrexate (n=54)* |
|---|---|---|
| Male, n (%) | 27 (48.2) | 33 (61.1) |
| Female, n (%) | 29 (51.8) | 21 (38.9) |
| Mean age±SD, years | 40.1±12.3 | 42.3±10.5 |
| White, n (%) | 52 (92.9) | 49 (90.7) |
| Asian, n (%) | 3 (5.4) | 5 (9.3) |
| Multiracial, n (%) | 1 (1.8) | 0 (0) |
| Mean BMI±SD, kg/m2 | 26.9±5.1 | 28.1±5.3 |
| Mean duration of PsA±SD, years | 2.8±2.6 | 3.7±2.7 |
| Mean swollen joint count±SD | 15.1±10.1 | 14.3±9.5 |
| Mean tender joint count±SD | 21.1±13.3 | 20.1±11.2 |
| Mean number of digits with dactylitis±SD | 3.3±4.2 | 3.1±4.2 |
| Mean number of assessment sites with enthesitis±SD (MASES) | 2.4±3.0 | 2.7±2.8 |
| Mean DAS28±SD | 5.16±1.1 | 5.07±1.2 |
| Mean fatigue/tiredness score±SD, VAS rating | 55.7±22.0 | 53.0±17.4 |
| Mean morning stiffness±SD, h | 1.46±0.87 | 1.13±0.58 |
| Mean HAQ–DI score±SD | 1.54±0.62 | 1.49±0.66 |
| Mean PASI±SD | 8.27±10.2 | 11.62±12.5 |
↵* Except for PASI score, where n=53.
BMI, body mass index; DAS28, disease activity score in 28 joints; HAQ–DI, health assessment questionnaire–disability index; ITT, intent to treat; MASES, Maastricht ankylosing spondylitis enthesitis score; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; VAS, visual analogue scale.